The Stanford Cardiovascular Institute (CVI) is pleased to announce the appointment of Philip Sager, MD, FACC, FAHA, FHRS, as CVI Consulting Professor effective July 15, 2013.  Dr. Sager performed his undergraduate work at MIT and attended medical school and completed his medical residency, cardiology, and electrophysiology fellowships at Yale University.  After a long academic career at UCLA, where his research focused on physiologic and drug-induced alterations in cardiac repolarization and was a tenured faculty member, he moved to the pharmaceutical industry. 

He played key leadership roles in the development of Zetia, Vytorin, Crestor, Letairis, Brilinta, and the Corus CAD diagnostic test.  He has deep expertise in the CV safety of drugs and was the ICH Expert Working Group PhRMA Topic Leader for the QT interval regulatory guidance (ICH E14) and is Chair of the Scientific Programs Committee and a member of the Executive Committee of the Cardiac Safety Research Consortium.

Dr. Sager is a voting member of the FDA Cardio-Renal Advisory Committee and is actively involved in developing collaborations between regulators, industry, and academia on new approaches to innovative drug development as well as CV safety assessment of pharmaceuticals and devices. He also has an interest in mobile health.  Dr. Sager will participate in collaborative research and teaching.